** Brokerage Needham raises PT on medical device maker iRhythm Technologies' shares to $112 from $96; maintains "buy" rating
** Raised PT represents 14.8% upside to stock's last close
** Brokerage forecasts Q4 revenue to be more than $160 mln vs est $157.5 mln - LSEG
** IRTC's heart monitoring devices, Zio monitor and Zio AT, drove company's strength in revenue forecast - brokerage
** Company forecast 2025 revenue between $675 mln and $685 mln, brokerage expects company will make "further progress on ramping profitability"
** Company's shares fell ~11% in 2024
(Reporting by Kamal Choudhury in Bengaluru) ((Kamal.Choudhury@thomsonreuters.com))
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。